• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

US - The race to protect endangered condors against deadly bird flu

Pathfinder

Editor, Senior Moderator
The Race to Protect Endangered Condors Against Deadly Bird Flu

Avian flu vaccines hadn’t been used on birds in the U.S. until condors started succumbing to the virus last year.

BY RENE EBERSOLE
10.04.2023

EARLY MARCH LAST YEAR, an endangered California condor — one of less than 350 of its kind surviving in the wild — perched on an Arizona cliff-face staring into space for days. It’s probably sick from lead poisoning, thought Tim Hauck, the condor program director with The Peregrine Fund, a nonprofit conservation group helping to reintroduce condors to the skies above Grand Canyon and Zion. These bald-headed scavengers — weighing up to 25 pounds with black-feathered wings spanning nearly 10 feet — often fall victim to lead exposure when they consume the flesh of cows, coyotes, and other large mammals killed by ranchers and hunters firing lead bullets. Listlessness and droopy posture are tell-tale signs. “We were like, I bet this bird’s got into something bad,” said Hauck.

His team of eight wildlife biologists stationed at Arizona’s scenic Vermillion Cliffs National Monument, 150 miles north of Flagstaff, hoped the ailing condor would glide down off its 1,000-foot sandstone ledge to visit their feeding station, where they could trap it to do a health examination. The Peregrine Fund provides supplemental food for the condors — most of which were raised in captivity and released into the wild — in part so the biologists can easily catch them for regular checkups, provide therapy for lead poisoning, vaccinate against West Nile virus, and update equipment used to track the condors’ whereabouts.

A week later, when the sick bird did finally get trapped at the feeding station, Hauck immediately noticed something he hadn’t seen before in lead-poisoned condors. Its eyes were cloudy, a condition called corneal edema. He consulted with Stephanie Lamb, a veterinarian who volunteers at Liberty Wildlife Center, a Peregrine Fund partner organization in Phoenix. He wanted to know if she thought the condor might be ill from something more worrisome than lead poisoning: highly pathogenic avian influenza, or HPAI, the virus responsible for the deaths of millions of wild birds and domestic chickens worldwide during the last two years. HPAI kills 90 to 100 percent of domestic poultry it infects, often within 48 hours, though less is known about the mortality rates for wild birds. Corneal edema, Lamb told him, was indeed on the list of symptoms.

Hauck’s team rushed the condor four-and-a-half hours south to the Liberty Wildlife Center’s quarantine for emergency care and testing. Then, as they were still waiting for the results, the situation in Vermillion Cliffs turned worse: A dead condor was spotted near a cave where she’d been nesting. The team recovered the carcass and immediately shipped it to the U.S. Fish and Wildlife Service Forensics Laboratory in Ashland, Oregon with an urgent request for an expedited necropsy. Recognizing the grave threat critically endangered California condors would face from an avian flu outbreak, the lab soon confirmed fears that the condor had succumbed to bird flu.

A wave of panic washed over Hauck and his crew. Condors are social creatures. They roost in groups and gather in hungry hoards to devour decaying animal corpses, sharing saliva and pooping everywhere. Hauck describes it as a “feeding frenzy” — ideal conditions for the disease to spread. What’s more, the virus thrives in damp, cold conditions; it had been a wet spring, and condors nest in caves, which tend to be humid and cooler than the outside air. Hauck worried that the disease, transmitted through the air and body fluids, would explode through the condor population “like wildfire.” He knew they had to contain it.
...
Working 14-hour days, climbing up cliffs, rappelling down canyons, and scouring the shores of the Colorado River by boat, they recovered dead condors almost daily. It felt like a nightmare that would never end, Hauck said. “It was a three-week period where we lost 21 birds.” Every carcass recovered tested positive for HPAI.

In less than a month, nearly 20 percent of the Southwest California condor population in Arizona and Utah had vanished. Conservationists worried that the virus would next strike condors in California. Then, as quickly as the virus flared up, it fizzled. With spring bird migration season winding down, and a return to hot, sunny days, Arizona’s condors stopped dying, and the condors in California were spared.

Recognizing that the outbreak could have been much worse — wiping out dozens more condors in multiple states, and possibly even killing animals in the captive-breeding flock kept in zoos — the U.S. Fish and Wildlife Service made a plea to the U.S. Department of Agriculture to authorize emergency use of an avian flu vaccine to inoculate condors in case of another outbreak.
...
The vaccine approved for the condors was developed in 2014, in response to the then-circulating H5N8 strain, with the idea that it would be used on commercial poultry. So that the vaccinated chickens would be distinguishable from chickens infected with H5N8, though, the scientists at Zoetis created the vaccine to protect against the H5N1 strain — a strategy that would still provide chickens with immunity, Lood said, while ensuring the virus wasn’t circulating silently. The vaccine was sold to the USDA’s vaccine bank but wasn’t used in the U.S. until wildlife managers were in sudden need of a vaccine to protect the condors against H5N1.

In May, federal biologists trapped 28 wild black vultures to be inoculated at the Carolina Raptor Center in Huntersville, North Carolina. Eight birds served as the controls, receiving no vaccine. Ten birds got half a standard dose, and a second half-dose 21 days later. The other 10 birds received just one shot, the preferred delivery for wild condors because they will need to be captured to receive their injection.

Each bird was placed in a special box designed to keep them calm and comfortable while waiting for their shot between the shoulder blades. By mid-July, there was good news: None of the black vultures showed adverse reactions, according to Blackford and Erin Katzner, founder and president of the Carolina Raptor Center, who hosted the trials. “When we get a tetanus shot, we get soreness and bruising,” Katzner said. “We didn’t see any swelling or bruising at the vaccine site for the vultures.”

The vaccine appears to be effective too: Results, which were released by FWS in August, showed 90 percent of the vultures that received two shots gained some immunity, compared to 70 percent of the single-dose birds.

With that positive news, the researchers began to administer the first shots to condors in captivity. To date, 20 of the condors have received vaccinations as part of the trial. Veterinarians are closely monitoring their health and collecting blood samples to see if they respond as well as the vultures.
...

https://undark.org/2023/10/04/condors-bird-flu/
 
EID Journal: Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against HPAI Virus, United States

EID Journal: Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against HPAI Virus, United States

AVvXsEhhzNPQkn3552l9Ywc6qKxIJpWZppx6pVMynNg28P69b5qJYbX0nC6DDHrdWk89pfzT84j7o6VF5pPC9KDxRRzeQltvor9jnOoAjKKKxFWtZgOfwmGvk1Xp2GlTA92QWEy33l03Fp-bMeIfyK6zsGM4Sd8VtZLlKK0CyYkBNyDtaQqNrWYIEfE=w285-h244

California Condor - Photo Credit Don Graham
#18,420

Just over two years ago (Apr 8th, 2023) the U.S. Fish & Wildlife Service issued a statement stating that HPAI Was Confirmed As Cause Of Death For 3 California Condors found in Northern Arizona.

Considered a critically endangered species with a population of≈ 560 birds today - the California Condor nearly went the way of of the Dodo in the early 1980s, when its population declined to just over 20 (in the wild)due to the combined effects of DDT, lead poisoning and a loss of habitat.​

This remarkable recovery was due to conservation efforts by the US Fish & Wildlife Service, the National Park Service, and breeding programs at San Diego's Wild Animal Park and the Los Angeles Zoo.



As scavengers, Condors feed almost exclusively on carrion, which increasingly runs the risk of being infected with HPAI H5 (see USDA Mammalian HPAI Infection List). Within days, the number of Condors deaths rose sharply.
(Excerpt)

As of April 17, 2023, 20 condors have died in the Arizona-Utah flock; HPAI has been confirmed for 10 of those condors. Eight birds were captured and brought in for supportive care. Four of those condors died shortly thereafter and are included in the total of 20 deceased birds.
Four condors are still receiving supportive care and have shown improvement. Learn more about HPAI.

In mid-May we looked at the USFWS & USDA Update On Impact of H5N1 on Condors & The Potential Use of HPAI Vaccines, which included plans to test an existing HPAI H5 poultry vaccine on vultures (a non-endangered species similar to Condors) in order to determine both its safety, and effectiveness against the currently circulating H5N1 virus (excerpt follows).

Over the summer we saw preliminary results on the vaccinated vultures, which were positive enough to allow a small test on captive condors.​

By October, we saw the Early HPAI Vaccine Results From Endangered California Condors, which reported that 60% of the condors (who received 2 doses) had titers that are expected to provide partial protection against mortality, while 10% of those birds had titers expected to provide protection against mortality.
On February 2nd, 2024 we saw our last substantive update from California Condor Recovery Program (excerpt below):

Based on the results of the vaccine trial, the Service determined it is appropriate to move forward with HPAI vaccinations of captively managed and free-flying condors. The Incident Command and recovery partners continue to coordinate on implementing vaccinations.

As of this report, 94 birds have received at least the initial dose of the vaccine. The vaccine is being administered with the prime and boost approach (vaccination of 0.5ml on two occasions a minimum of 21 days apart). All condors are vaccinated by veterinarians licensed in the state according to USDA/State Veterinarian-approved site-specific plans.

Antibody titers collected during the trial indicate the vaccine may reduce the severity of an infection and minimize the likelihood of mortality. Vaccinating condors with the approved vaccine may provide some protection, and even if minimal, it could reduce the amount of mortality and decrease the impact to the flock and recovery efforts if another outbreak were to occur.

All of which brings us to a research report - published yesterday in the EID Journal - which describes the vaccine trials in Vultures (and later in Condors) and provides far greater details on the results.
Although condors did not respond to the vaccines as robustly as did black vultures, 16 (80%) of the 20 vaccinated condors seroconverted sometime during the 42-day test window, with 9 (45%) achieving HI titers >32 (thought capable of protecting against mortality) on at least 1 of the postvaccination blood draws.​

While promising, there remain a lot of unanswered questions, including:
  • How much real-world protection is afforded to condors from vaccination?
  • How long does this protection last?
  • How practical is it to capture, vaccinate, and release wild endangered birds? And how might that impact its effectiveness vs. vaccinating captive birds?
  • What impact (if any) might come from viral shedding from partially protected birds?
This is a lengthy, and at times technical, report. I've only reproduced the Abstract and the Discussion. Follow the link to read it in its entirety. I'll have a postscript after the break.

Research
Safety and Immunogenicity of Poultry Vaccine for Protecting Critically Endangered Avian Species against Highly Pathogenic Avian Influenza Virus, United States

Todd E. Katzner , Ashleigh V. Blackford, Mary Donahue, Samantha E.J. Gibbs, Julianna Lenoch, Michael Martin, Tonie E. Rocke, J. Jeffrey Root, Darrel Styles, Sunny Cooper, Kristin Dean, Zachary Dvornicky-Raymond, Dominique Keller, Carlos Sanchez, Brett Dunlap, Thomas Grier, Michael P. Jones, Gregory Nitzel, Erin Patrick, Maureen Purcell, Aaron J. Specht, and David L. Suarez

Abstract

In 2023, an outbreak of highly pathogenic avian influenza occurred among critically endangered California condors (Gymnogyps californianus), and >21 died. We evaluated safety, immunogenicity, vaccination strategies, and correlates of antibody response of an influenza vaccine for poultry in black vultures (Coragyps atratus) and then California condors.


We noted differences in antibody titers between vaccinated and unvaccinated birds (vultures p<0.004; condors p­<0.02) but no adverse effects of vaccination. All vaccinated vultures and 80% of vaccinated condors showed maximum measured antibody response within the published range associated with survival of vaccinated and virally challenged chickens. We noted weak evidence of higher antibody responses for birds given two 0.5-mL vaccines versus those given one 1-mL vaccine but no correlation between antibody titers and sex for either species or between antibody titers and bone lead concentrations in vultures. Our results prompted initiation of a vaccination program for condors that could reduce spread of this disease among highly threatened species.

Discussion

Many types of HPAIV vaccines have been developed (26), including inactivated whole virus vaccines, subunit vaccines, and live vectored viral vaccines (27). Risk analysis for this vaccination trial included consideration of the potential to stimulate a protective immune response, legal availability of the vaccine, and the antigenic relatedness of vaccines to a potential field challenge. That approach led us to select the inactivated adjuvanted reverse genetics vaccine for this trial because it safely stimulated immune responses in multiple avian species and because it has ≈95.6% amino acid similarity to the currently circulating H5N1 2.3.4.4b virus isolates.

Although nearly all birds of both species responded immunologically to the vaccine, the generally stronger short-term antibody responses of black vultures compared with California condors are notable. Interspecific differences are not surprising because vaccines developed for one species can have unexpected effects in other species and related species can have substantially different responses to vaccination (28). Despite those differences, maximum HI titers of vultures given a 2-vaccine regimen were similar to those reported for domestic fowl given a similar vaccination regimen (i.e., vulture maximum titers were 32–512, chicken titers at 42 dpv were 16–1,024) (18). Similarly, maximum titers of condors given a 2-vaccine regimen were 8–64, and all but 1 titer was within the lower end of the range reported for chickens.

Work with endangered species presents many hurdles and often precludes the possibility of testing the effectiveness of a vaccine with a viral challenge (29). Furthermore, because of the dramatic impacts of HPAI on wild condors, we conducted the trials rapidly and in an extremely urgent context. Together with biosafety considerations, those issues made it impractical to conduct a logistically difficult viral challenge for the vultures or to evaluate longer-term immune response. However, we can draw inference from prior work with this vaccine. As we noted, 100% of chickens given this same vaccine responded with similar antibody levels and survived a viral challenge at 42 dpv (18). Given the similarity of those responses, had a viral challenge at 42 dpv had been feasible, we reason that most if not all vultures, and perhaps condors, would likely have survived.

The vaccine we evaluated was developed for prime-boost (2-vaccine) application. However, because trapping and handling can stress condors, we evaluated a 1-vaccine regimen as an alternative to the originally designed regimen. Despite the lack of a statistical difference between antibody responses associated with the 2 regimens, qualitative evaluation suggested that antibody responses were weaker and dissipated more rapidly for the birds that received the 1-vaccine regimen. Thus, we suspect that if birds were given a viral challenge, birds that received prime and boost vaccinations would have been more effectively protected than those vaccinated once. However, because our study ended at 42 dpv, we could not evaluate the potential for differences in waning immunity (30) between the 2 vaccine strategies.

Our failure to detect a statistical effect of either sex or bone lead concentration on antibody response might have been because of the small sample sizes and skewed sex ratios in our trials. Trends in the data suggested that if our sample size had been larger and the sex ratios more even, we might have detected differences in responses between sexes. Likewise, in the case of the response to bone lead concentrations, the statistical approach we used might not have uncovered difficult-to-detect patterns. We noted that, regardless of vaccine regimen, the birds with the strongest antibody response were also those with the lowest bone lead level. Therefore, subsequent trials might evaluate the presence of threshold-type effects in those responses.

Given the virulence and spread of the currently circulating HPAIV, vaccination of threatened and endangered wild birds could be a potential tool to mitigate losses from this disease. Vaccination may be particularly relevant when the resiliency of populations has decreased to the extent that naturally occurring illness and death from disease could impair the species’ long-term persistence. Despite the potential value of that approach, negative consequences of vaccination are possible, and this trial and implementation in the condor program are unique within the United States.

Given the importance of economic considerations associated with poultry farming, close coordination with the USDA and many other federal and state agencies was essential to receive authorization to implement these vaccination trials. However, the outcomes from these trials were positive enough, and the threat from HPAIV so great, that the USFWS subsequently decided to initiate a vaccination program for the California Condor Recovery Program (11). By October 2024, a total of 207 condors had received >1 vaccination (30).

Species-specific variations in physiological response to vaccination are characteristic problems associated with vaccination programs for wildlife (31). Despite such variations, evidence suggests that vaccination strategies that reach <50% of an affected wildlife population can still be effective at staving off extinction (32,33). Those trends, together with results of our work, suggest several next steps for protecting endangered wildlife, whether condors or other species, from infectious diseases. Vaccination of the at-risk population of the target species can begin once safety, immunogenicity, and vaccination regimens have been established and some correlate of protection established, either from published work with other species or from direct challenge trials.

Critical next steps include monitoring vaccine effectiveness in field settings and demographic modeling to understand the most effective strategy for vaccination of wild animals. Specifically, given the challenges inherent in vaccinating wild animals, using life history traits of the species in question, together with population modeling, can confirm the costs and benefits of vaccination in relation to its risks and, thus, can help identify vaccination strategies that can stabilize populations and enable them to recover. Relevant vaccination strategies might involve varying the time of year (especially relative to reproductive seasons and seasonal variation in survivorship), age classes, and proportion of the population that is vaccinated.

In summary, we evaluated safety, immunogenicity, vaccination regimens, and correlates of antibody response for a conditionally licensed influenza subtype H5N1 vaccine designed for poultry in black vultures and California condors. Our work suggests that the use of licensed vaccines can be a realistic strategy to aid in conservation of condors and potentially other species facing similar threats, especially those with small and highly threatened populations.

Dr. Katzner is a research wildlife biologist at the USGS, Forest and Rangeland Ecosystem Science Center in Boise, Idaho, USA. His research interests focus on birds of prey, renewable energy, and conservation biology.


While these results would be underwhelming in commercial poultry, they could be good enough to prevent the loss of an endangered species threatened by HPAI H5.

The stark difference in HI titers >32 between vultures (90%) and condors (60%) receiving two doses of the vaccine is a reminder that one size rarely fits all, and that there is more work to be done on refining H5 vaccines.​

Given that HPAI isn't likely to go away anytime soon, creating more effective vaccines that are protective across a wider range of species should remain a priority.

https://afludiary.blogspot.com/2025/04/eid-journal-safety-and-immunogenicity.html
 
Back
Top